NASDAQ · Biotechnology · USD
Soligenix, Inc. (SNGX) Stock Analysis
Soligenix, Inc. (SNGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SNGX Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.34
- Previous Close
- $0.35
- Day's Range
- 0.34–0.37
- 52-Week Range
- 0.28–1.70
- Volume
- 59.09K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.00
Valuation
- Market Cap
- $7.62M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.79
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$11.08M
- Shares Outstanding
- 21.77M
- 1-Year Return
- −78.78%
Dividend and dates
- Avg Volume
- 221.79K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, SNGX closed at $0.35, −78.78% over 1 year.
Soligenix, Inc. (SNGX) has a market capitalization of $7.62M.
In fiscal 2025, SNGX reported revenue of $0.00.
SNGX Stock Return by Calendar Year
Soligenix, Inc. (SNGX) 10-year return: what $10,000 became
- 1 year
- $10,000 $2,122
- −78.78%
- 5 years
- $10,000 $14
- −99.86%
- 10 years
- $10,000 $3
- −99.97%
If you had invested $10,000 in Soligenix, Inc. (SNGX) 10 years ago, at the close on October 21, 2016, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −55.69% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −73.87% |
| 2025 | −50.37% |
| 2024 | −77.80% |
| 2023 | −88.74% |
| 2022 | −31.82% |
| 2021 | −48.44% |
| 2020 | −11.72% |
| 2019 | +68.60% |
| 2018 | −61.26% |
| 2017 | −1.33% |
| 2016 (partial year) | −63.11% |
As of October 21, 2026.
SNGX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$11.08M | — |
| 2024 | $0.00 | −$8.27M | — |
| 2023 | $0.00 | −$6.14M | — |
| 2022 | $250.00K | −$13.80M | −5,519.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | −$11.85M | −$11.08M | — |
| 2024 | $0.00 | −$119.37K | −$9.46M | −$8.27M | — |
| 2023 | $0.00 | −$742.05K | −$7.67M | −$6.14M | — |
| 2022 | $250.00K | −$300.82K | −$14.11M | −$13.80M | −5,519.3% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B